TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. - Wikidata - awgldk - TriplyDB

TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.

TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.

http://www.wikidata.org/entity/Q37384724

about

Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.Recent advances in recombinant protein-based malaria vaccines.An overview of adjuvant formulations and delivery systems.Increased Plasmodium falciparum Parasitemia in Non-splenectomized Saimiri sciureus Monkeys Treated with Clodronate Liposomes.Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.

P2860

Q28972540-64484623-2BEC-4193-A259-C9BF3DB3B7D2 Q34414790-2ACD7924-07EA-44E8-8F9F-8C2C4E290071 Q36035012-B004AA28-5DDC-4012-A804-FBAF12676D39 Q36394182-F60587F8-C313-4293-8EB2-3160C298DD96 Q38126953-8022DF5E-010E-47EB-BA13-1AF33E146576 Q41842496-CAA0D887-409E-475D-B244-62C6969D476C Q52714411-C502B2D2-47DD-42FD-9AFB-2132D55AD424

P2860

TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.

http://www.wikidata.org/entity/Q37384724

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@en

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@nl

type

label

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@en

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@nl

prefLabel

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@en

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@nl

P1433

Q37384724-2A5C98BF-9DE7-42D4-8AC7-5DBB3598B492

P1476

Q37384724-3DD874B0-2539-4904-8695-0A9C59ECCCE4

P2093

Q37384724-162696B4-60F9-4B75-A151-327CA895E5F8

Q37384724-366742E5-91FD-4CDE-9CD8-CF0834A6A584

Q37384724-8574D5B6-BBA7-459E-A418-EFBFF5D977CC

Q37384724-F45C2CFF-3199-4386-B406-CAD770174C51

Q37384724-F69AB7D9-9814-4A89-B48B-19B2D4F882CB

P2860

Q37384724-0530A479-9FC8-4B8C-977A-8BE23C5D4BE7

Q37384724-0A1F7344-2235-4BF3-BE57-E3AFAC982DEB

Q37384724-0CA3E015-6C70-4734-B4B9-7A6D0FECDF8C

Q37384724-1C04B247-7F04-4490-B4BB-88AB13007D52

Q37384724-2FFA8825-E51C-401C-A3CF-34E989C5850A

Q37384724-33130E8C-30C0-465B-8CEC-1DC43B6C2BEB

Q37384724-3842A4A0-2AFB-4624-8511-8996BF9050FC

Q37384724-5584A7FB-F414-47C7-A07A-9EF68B92D2C1

Q37384724-559B04BF-BCA5-4D96-9AE2-D7CBF168DFF6

Q37384724-5AA22CD2-7061-4C3C-AB71-D7639FB7183C

P304

Q37384724-9409C856-A5C5-4DE5-911D-1AFB1660265F

P31

Q37384724-236E0937-2BF2-413F-AE1C-9180B1723CBA

P356

Q37384724-1078B58E-D315-4B38-841A-8D6C7257C87D

P433

Q37384724-67ABEBC9-4317-40B7-82E7-5D2C6E3EFCA1

P478

Q37384724-266D1125-FC03-4AF9-876D-EC26B6195490

P50

Q37384724-06B8C880-0E9B-4A96-8E76-D23FD20F4DA2

Q37384724-83946354-E07F-4703-BF99-F78B90082DFB

Q37384724-AD17FFCC-D010-41CF-BA10-7A3FA350AD7F

P577

Q37384724-21A59514-7EAC-4014-AFEC-0718A9411B4F

P5875

Q37384724-3CE4F856-4999-44A8-A296-60EAF6096D25

P698

Q37384724-DF0FAE31-5FAC-4A5C-AAC0-8C836346F06E

P921

Q37384724-8A3A9F48-9E30-4AC7-9552-2204BF7D2F29

Q37384724-D132385E-1A68-4EA5-8EF9-95B88EC70DB2

P932

Q37384724-C3408D0E-AB11-4450-8BA4-8EAA54C60833

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

TLR9 adjuvants enhance immunog ...... ne in nonhuman primate models.

@en

P2093

Chieko Kai

http://www.w3.org/2001/XMLSchema#string

Taiki Aoshi

http://www.w3.org/2001/XMLSchema#string

Takahiro Tougan

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Yasutomi

http://www.w3.org/2001/XMLSchema#string

Yuko Katakai

http://www.w3.org/2001/XMLSchema#string

P2860

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity.

Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant.

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria.

Antibodies reactive with the N-terminal domain of Plasmodium falciparum serine repeat antigen inhibit cell proliferation by agglutinating merozoites and schizonts.

Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum.

P304

283-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.22950

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Toshihiro Horii

P577

2013-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234069632

http://www.w3.org/2001/XMLSchema#string

P698

23291928

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

3859748

http://www.w3.org/2001/XMLSchema#string